TITLE

Management of Severe Gastrointestinal Tuberculosis with Injectable Antituberculous Drugs

AUTHOR(S)
Goldani, Luciano Z.; Spessatto, Camila O.; Nunes, Daltro L.; Oliveira, Juliana G.; Takamatu, Eliziane; Cerski, Carlos T.; Goldani, Helena A. S.
PUB. DATE
July 2015
SOURCE
Tropical Medicine & Health;2015, Vol. 43 Issue 3, p191
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abdominal tuberculosis (TB) is generally responsive to medical treatment, and early diagnosis and management can prevent unnecessary surgical intervention. However, intravenous therapy is needed for severe forms of tuberculosis with extensive gastrointestinal involvement. The authors report an immunocompetent patient with gastrointestinal TB who was successfully managed with a combination of surgical intervention and anti-TB medications, and discuss the importance of injectable anti-TB medications in the management of severe gastrointestinal TB. The present case report provides a model for assessment and intervention in severe forms of gastrointestinal TB.
ACCESSION #
110831751

 

Related Articles

  • Intermittent Directly Observed Therapy for Abdominal Tuberculosis: A Multicenter Randomized Controlled Trial Comparing 6 Months Versus 9 Months of Therapy. Makharia, Govind K.; Ghoshal, Uday C.; Ramakrishna, Balakrishnan S.; Agnihotri, Abhishek; Ahuja, Vineet; Chowdhury, Sudipta Dhar; Gupta, Siddhartha Datta; Mechenro, John; Mishra, Asha; Pathak, Manish K.; Pandey, Ravinder M.; Sharma, Raju; Sharma, and Surendra K. // Clinical Infectious Diseases;9/1/2015, Vol. 61 Issue 5, p750 

    Background. The duration of treatment of gastrointestinal tuberculosis continues to be a matter of debate. The World Health Organization advocates intermittent directly observed short-course therapy (DOTs), but there is a lack of data of its efficacy in abdominal tuberculosis. We therefore...

  • Combination TB drug approved.  // FDA Consumer;Sep94, Vol. 28 Issue 7, p2 

    Comments on approval by the Food and Drug Administration (FDA) of Rifater, a product that combines three existing tuberculosis drugs into a single tablet. Why this fixed-dose product was developed.

  • tuberculostatic.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2385 

    A definition of the medical term "tuberculostatic," which refers to inhibiting the growth of tubercle bacillus, is presented.

  • High prevalence of resistance to second-line anti-TB drugs.  // Reactions Weekly;9/8/2012, Issue 1418, p4 

    The article reports on the Preserving Effective TB Treatment Study (PETTS) which reveals that the prevalence of resistance to second-line antituberculosis drugs is high.

  • Ethionamide.  // Reactions Weekly;7/6/2013, Issue 1460, p22 

    The article presents a case study of a 38-year-old man who developed gynaecomastia while receiving ethionamide and antituberculars for the treatment of pulmonary tuberculosis.

  • Are free anti-tuberculosis drugs enough? An empirical study from three cities in China. Shanquan Chen; Hui Zhang; Yao Pan; Qian Long; Li Xiang; Lan Yao; Lucas, Henry // Infectious Diseases of Poverty;10/28/2015, Vol. 4, p1 

    Background: Tuberculosis (TB) patients in China still face a number of barriers in seeking diagnosis and treatment. There is evidence that the economic burden on TB patients and their households discourages treatment compliance. Methods: A cross-sectional study was conducted in three cities of...

  • Treating TB today. King, Michalene A.; Tomasic, Diane M.; Moore, Amy Slugg // RN;Jun99, Vol. 62 Issue 6, p26 

    Discusses the management of tuberculosis in the United States. Infection control practices; Mode of transmission; Individuals at risk of infection; Screening of tuberculosis; Anti-tuberculosis drugs; Patient education.

  • In vivo veritas: The search for TB drug targets goes live. McKinney, John D. // Nature Medicine;Dec2000, Vol. 6 Issue 12, p1330 

    The term 'microbial persistence' describes a phenomenon whereby microorganisms which are drug-susceptible when tested outside the body are nevertheless capable of surviving within the body despite intensive therapy with the appropriate antimicrobial drug. In clinical practice this phenomenon...

  • Ethambutol/isoniazid/pyrazinamide/rifampicin.  // Reactions Weekly;5/5/2012, Issue 1400, p20 

    The article describes the case of a patient who developed paradoxical worsening of cutaneous lesions after receiving antitubercular therapy for miliary tuberculosis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics